The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications

The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications

<i>Background and Objectives</i>: The ever-expanding entry of biosimilar drugs into the Israeli market requires doctors to decide whether to prescribe these medications. We aimed to assess the prevalence of biosimilar use and Israeli gastroenterologists’ knowledge, experience, and percep...

Full description

Bibliographic Details
Main Authors:	Vered Richter, Daniel L. Cohen, Anton Bermont, Tzippi Shalem, Efrat Broide, Haim Shirin
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Medicina
Subjects:	biosimilar drugs inflammatory bowel disease treatment perception
Online Access:	https://www.mdpi.com/1648-9144/59/3/523

Similar Items

Position statement on the use of biosimilars in inflammatory bowel disease
by: Emanuel Burri, et al.
Published: (2019-12-01)

Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease
by: Federico Argüelles-Arias, et al.

Current status of biosimilars in the treatment of inflammatory bowel diseases
by: Dong Il Park
Published: (2016-01-01)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
by: Al Sulais E, et al.
Published: (2020-01-01)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
by: Thomas Khoo, et al.
Published: (2022-12-01)

Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary
by: Richard H. Parrish
Published: (2021-06-01)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
by: Yannick Vandenplas, et al.
Published: (2022-01-01)

Biosimilars and the extrapolation of indications for inflammatory conditions
by: Tesser JRP, et al.
Published: (2017-02-01)

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
by: Daniel C. Baumgart, et al.
Published: (2019-03-01)

Are We Ready for Biosimilars in Gastroenterology?
by: Muhammad Ilham Abdul Hafidz, et al.
Published: (2017-12-01)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
by: Marta Vernero, et al.
Published: (2023-10-01)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
by: Valeria Dipasquale, et al.
Published: (2022-03-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
by: Anna Pękala, et al.
Published: (2021-06-01)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
by: Anna Felis-Giemza, et al.
Published: (2019-10-01)

Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing
by: Dmitry Karateev, et al.
Published: (2019-02-01)

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge
by: Vered Richter, et al.
Published: (2024-02-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
by: Tim A. Kanters, et al.
Published: (2017-05-01)

Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey
by: Steve Fenwick, et al.
Published: (2019-02-01)

Biosimilar insulins in international and domestic practice of pharmacist
by: I. O. Vlasenko, et al.
Published: (2022-02-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
by: Cohen SB, et al.
Published: (2023-10-01)

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
by: Eva Rahman Kabir, et al.
Published: (2019-08-01)

DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: Natália Sousa Freitas QUEIROZ, et al.
Published: (2020-09-01)

Los biológicos y los biosimilares
by: Carlos Rios Acosta
Published: (2017-06-01)

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01)

Ten years of biosimilar recombinant human growth hormone in Europe
by: Saenger P
Published: (2017-05-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

A practical guide about biosimilar data for health care providers treating inflammatory diseases
by: Markenson J, et al.
Published: (2017-02-01)

Triunfalismo del decreto de los Biosimilares
by: Carlo Vinicio Caballero Uribe
Published: (2014-01-01)

Biosimilars: potential implications for clinicians
by: Eleryan MG, et al.
Published: (2016-06-01)

A Novel Model to Predict Inadequate Bowel Preparation Prior to Colonoscopy Incorporating Patients’ Reactions to Drinking the Laxative
by: Daniela Malkin, et al.
Published: (2023-11-01)